Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Receives $33.06 Consensus Price Target from Analysts

Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) have earned an average rating of “Hold” from the eighteen ratings firms that are covering the company, MarketBeat.com reports. Two investment analysts have rated the stock with a sell recommendation, seven have given a hold recommendation and nine have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $33.0625.

Several analysts have recently commented on the company. Weiss Ratings restated a “sell (e+)” rating on shares of Apellis Pharmaceuticals in a report on Wednesday, October 8th. The Goldman Sachs Group downgraded shares of Apellis Pharmaceuticals from a “neutral” rating to a “sell” rating and reduced their price target for the stock from $26.00 to $18.00 in a research report on Friday, September 26th. TD Cowen decreased their price objective on shares of Apellis Pharmaceuticals from $50.00 to $45.00 and set a “buy” rating on the stock in a report on Friday, October 31st. Wall Street Zen raised shares of Apellis Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. Finally, HC Wainwright reduced their target price on shares of Apellis Pharmaceuticals from $57.00 to $45.00 and set a “buy” rating on the stock in a research report on Friday, October 31st.

Apellis Pharmaceuticals Stock Performance

NASDAQ:APLS opened at $19.81 on Tuesday. The stock has a market capitalization of $2.51 billion, a P/E ratio of 63.91 and a beta of 0.70. The company has a current ratio of 3.54, a quick ratio of 3.10 and a debt-to-equity ratio of 0.90. Apellis Pharmaceuticals has a 1 year low of $16.10 and a 1 year high of $35.72. The firm has a 50 day moving average of $24.05 and a 200-day moving average of $21.81.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its quarterly earnings results on Thursday, October 30th. The company reported $1.67 EPS for the quarter, topping analysts’ consensus estimates of $1.03 by $0.64. Apellis Pharmaceuticals had a return on equity of 18.94% and a net margin of 4.43%.The business had revenue of $458.58 million for the quarter, compared to analyst estimates of $364.58 million. During the same period in the prior year, the company earned ($0.46) EPS. Apellis Pharmaceuticals’s revenue for the quarter was up 133.0% on a year-over-year basis. As a group, sell-side analysts anticipate that Apellis Pharmaceuticals will post -1.7 EPS for the current fiscal year.

Insider Transactions at Apellis Pharmaceuticals

In other news, General Counsel David O. Watson sold 5,000 shares of the business’s stock in a transaction on Thursday, October 16th. The stock was sold at an average price of $25.22, for a total transaction of $126,100.00. Following the completion of the sale, the general counsel owned 113,730 shares in the company, valued at $2,868,270.60. The trade was a 4.21% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Timothy Eugene Sullivan sold 10,000 shares of the company’s stock in a transaction on Tuesday, October 21st. The shares were sold at an average price of $28.03, for a total value of $280,300.00. Following the transaction, the chief financial officer directly owned 110,936 shares in the company, valued at $3,109,536.08. This trade represents a 8.27% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 312,921 shares of company stock worth $8,490,866 in the last quarter. 6.50% of the stock is owned by corporate insiders.

Institutional Trading of Apellis Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. PNC Financial Services Group Inc. lifted its position in Apellis Pharmaceuticals by 0.8% during the 2nd quarter. PNC Financial Services Group Inc. now owns 58,856 shares of the company’s stock valued at $1,019,000 after purchasing an additional 465 shares during the period. Amalgamated Bank raised its position in shares of Apellis Pharmaceuticals by 6.9% during the 3rd quarter. Amalgamated Bank now owns 8,674 shares of the company’s stock valued at $196,000 after acquiring an additional 563 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Apellis Pharmaceuticals by 15.6% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,855 shares of the company’s stock valued at $84,000 after purchasing an additional 655 shares during the period. Parallel Advisors LLC lifted its stake in shares of Apellis Pharmaceuticals by 80.0% in the 2nd quarter. Parallel Advisors LLC now owns 1,924 shares of the company’s stock valued at $33,000 after purchasing an additional 855 shares during the period. Finally, Baird Financial Group Inc. boosted its position in shares of Apellis Pharmaceuticals by 1.6% in the 1st quarter. Baird Financial Group Inc. now owns 55,529 shares of the company’s stock worth $1,214,000 after purchasing an additional 864 shares during the last quarter. 96.29% of the stock is currently owned by institutional investors and hedge funds.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).